Abbott’s breakthrough viral load testing product brings fast, accurate results in remote areas.
Jul 24 2018
Imagine a woman living with HIV walking 10 kilometers in intense heat
to get to a health clinic to take a test that measures the amount of
HIV in her body. Then she has to walk back the same distance again a few
weeks later to get her test results. Think about the physical hardships
of her journey. Imagine the emotional and mental strain as she travels
to find out whether her HIV treatment has been successful.
the plight of millions of people living with HIV in resource-limited
areas of sub-Saharan Africa, Asia and Latin America.
However, this no longer needs to be the case.
Abbott’s newest solution, the m-PIMA? HIV-1/2 VL
is the first viral load monitoring test at the point of care. It has
been designed to provide healthcare professionals – especially in remote
and underserved communities – with a fast, accurate, and easy-to-use
test to help manage their patients’ HIV.
The m-PIMA? HIV-1/2 VL
test joins Abbott’s broad portfolio of HIV diagnostic solutions that
span the entire continuum of care for people at risk of and living with
HIV. Diagnostics are a vital component of a holistic effort to achieve
the UNAIDS 90-90-90 Goals and end the AIDS epidemic by 2030.
integration of point-of-care viral load solutions in healthcare
networks will be instrumental in achieving UNAIDS’ 90-90-90 goals," said
Professor Matilu Mwau, Director at the Center for Infectious and
Parasitic Diseases Control Research, Kenya Medical Research Institute
(KEMRI) in Busia, Kenya. "Viral load testing is critical for the
monitoring of individual treatment response, the effective use of costly
antiretroviral medications, and to track the emergence of resistance in
people who are HIV-positive."1
Portable and robust,
the m-PIMA platform can help address issues around infrastructure
obstacles, shortage of skilled clinicians, logistical challenges and
inefficient systems for providing results to patients.
HIV-1/2 VL test is now commercially available in select countries. Data
has been submitted for CE-IVD marking and WHO prequalification. This
product is not available in the United States.
1 UNAIDS (2014) 90-90-90 An ambitious target to help end the AIDS epidemic. Available on http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.